Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) signed a licensing pact with Inserm Transfert. The exclusive license allows Tonix to use oxytocin based therapeutics to cure Prader Willi Syndrome. It also allows the treatment of non-organic failure.
Inserm Transfert is a private ancillary of the FNIHHMR (French National Institute of Health and Medical Research) called Inserm. It negotiated and signed a licensing pact with Tonix for value creation.
The exclusive license allows expansion of TNX-2900
Tonix can make use of a co-exclusive license for expanding its intranasal potentiated oxytocin development program for a new indication. The company designated the new program as TNX-2900 and will be used to cure Prader Willi Syndrome.
Market exclusivity for co-licensees
The patent that covers this technology allows Tonix with market exclusivity through the year 2031 in Europe and the US. Tonix can further extend the market exclusivity through SPC (supplemental protection certificate) in Europe. It can also extend the term of the patent in the US without affecting its other patents that cover oxytocin potentiation technologies and formulation for intranasal administration.
Seth Lederman, CEO and President of Tonix said no approved treatments are available in the market for the rare genetic disorder – Prader Willi Syndrome that causes uncontrolled hunger in adulthood and childhood. If it is not cured, it could cause obesity because of uncontrolled appetite. The company can capitalize on this untapped market opportunity using the exclusive license obtained from Inserm Transfert and develop intranasal potentiated oxytocin to a new indication.
The orphan disease affects one in 15,000 births
One in 15,000 infants is diagnosed with Prader Willi Syndrome. The company will submit IND for this treatment at an appropriate time to the US FDA. Children and adults suffering from Prader Willi Syndrome suffer from mental, physical, and behavioral problems. They experience poor muscle strength and a lack of suckling. It causes malnutrition in children. Tonix will provide intranasal oxytocin to enhance suckling in newborns.
Tonix developed TNX-2900 using its patented IPX (intranasal potentiated oxytocin) formulation. The company is also developing TNX-1900 to treat insulin resistance and prophylaxis of chronic migraine. Reduced oxytocin levels in the human body could cause an increased frequency of headaches. The new drug developed by Tonix will improve oxytocin levels and cures headache.
